Paediatric idiopathic inflammatory muscle disease

Best Practice and Research: Clinical Rheumatology

Volumn 18, Issue 3, 2004, Pages 345-358

  Wedderburn, Lucy R ^a   Li, Charles K C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Activity; Damage; Dermatomyositis; Idiopathic inflammatory muscle disease; Juvenile; Major histocompatability complex; Myopathy

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PAMIDRONIC ACID; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG ABSORPTION; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MYOSITIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION PROCESS;

CHILD; HUMANS; MYOSITIS;

EID: 3242717972     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.01.003     Document Type: Review

References (68)

1. Oddis C.V. Conte C.G. Steen V.D. et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982 Journal of Rheumatology 17 1990 1329-1334
2. Medsger T.A. Jr Dawson W.N. Jr Masi A.T. The epidemiology of polymyositis American Journal of Medicine 48 1970 715-723
3. Symmons D.P. Sills J.A. Davis S.M. The incidence of juvenile dermatomyositis: results from a nation-wide study British Journal of Rheumatology 34 1995 732-736
4. Mendez E.P. Lipton R. Ramsey-Goldman R. et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry Arthritis and Rheumatism 49 2003 300-3005
5. Cassidy J.T. Petty R.E. Juvenile dermatomyositis In Cassidy J.T. Petty R.E. (Eds.), Textbook of Pediatric Rheumatology 2001 W.B. Saunders London
6. See Y. Giam Y.C. Chng H.H. A retrospective study of 13 Oriental children with juvenile dermatomyositis Annals of the Academy of Medicine of Singapore 26 1997 210-214
7. Shehata R. al-Mayouf S. al-Dalaan A. et al. Juvenile dermatomyositis: clinical profile and disease course in 25 patients Clinical and Experimental Rheumatology 17 1999 115-118
8. Porkodi R. Shanmuganandan K. Parthiban M. et al. Clinical spectrum of inflammatory myositis in South India-a ten year study Journal of the Association of Physicians of India 50 2002 1255-1258
9. Tse S. Lubelsky S. Gordon M. et al. The arthritis of inflammatory childhood myositis syndromes Journal of Rheumatology 28 2001 192-197
10. Bohan A. Peter J.B. Polymyositis and dermatomyositis. I New England Journal of Medicine 292 1975 344-347
11. Targoff I.N. Miller F.W. Medsger T.A. Jr et al. Classification criteria for the idiopathic inflammatory myopathies Current Opinion in Rheumatology 9 1997 527-535
12. Pachman L.M. Hayford J.R. Chung A. et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children Journal of Rheumatology 25 1998 1198-1204
13. Li C. Varsani H. Holton J. et al. MHC class I over-expression on muscles in early juvenile dermatomyositis Journal of Rheumatology 31 3 2004 605-609
14. Rider L.G. Miller F.W. Classification and treatment of the juvenile idiopathic inflammatory myopathies Rheumatic Diseases Clinics of North America 23 1997 619-655
15. Kimball A.B. Summers R.M. Turner M. et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy Arthritis and Rheumatism 43 2000 1866-1873
16. Targoff I.N. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies Rheumatic Diseases Clinics of North America 28 2002 859-890
17. Feldman B.M. Reichlin M. Laxer R.M. et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis Journal of Rheumatology 23 1996 1794-1797
18. Chmiel J.F. Wessel H.U. Targoff I.N. et al. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody Journal of Rheumatology 22 1995 762-765
19. Ramanan A.V. Feldman B.M. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes Rheumatic Diseases Clinics of North America 28 2002 833-857
20. Trapani S. Camiciottoli G. Vierucci A. et al. Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study Rheumatology 40 2001 216-220
21. See Y. Martin K. Rooney M. et al. Severe juvenile dermatomyositis complicated by pancreatitis British Journal of Rheumatology 36 1997 912-916
22. Laskin B.L. Choyke P. Keenan G.F. et al. Novel gastrointestinal tract manifestations in juvenile dermatomyositis Journal of Paediatrics 135 1999 371-374
23. Sallum A.M. Kiss M.H. Sachetti S.et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients Arquivos de Neuro-Psiquiatria 60 2002 889-899
24. Huemer C. Kitson H. Malleson P.N. et al. Lipodystrophy in patients with juvenile dermatomyositis - evaluation of clinical and metabolic abnormalities Journal of Rheumatology 28 2001 610-615
25. Smith R. Sundberg J. Shamiyeh E. et al. Skin involvement in JDM is associated with nailfold capillaroscopy (NFC) abnormalities Arthritis and Rheumatism 46 2002 S306
26. Dolezalova P. Young S.P. Bacon P.A. et al. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study Annals of the Rheumatic Diseases 62 2003 444-449
27. Blaszczyk M. Jablonska S. Szymanska-Jagiello W. et al. Childhood scleromyositis: an overlap syndrome associated with PM-Scl antibody Pediatric Dermatology 8 1991 1-8
28. Lovell D.J. Lindsley C.B. Rennebohm R.M.et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group Arthritis and Rheumatism 42 1999 2213-2219
29. Feldman B.M. Ayling-Campos A. Luy L. et al. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire Journal of Rheumatology 22 1995 326-331
30. Rider L.G. Assessment of disease activity and its sequelae in children and adults with myositis Current Opinion in Rheumatology 8 1996 495-506
31. Ruperto N. Ravelli A. Murray K.J. et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis Rheumatology 42 2004 1452-1459
32. Isenberg D.A. Allen E. Farewell V. et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease Rheumatology 43 2004 49-54
33. Pilkington C. Murray K.J. Isenberg D. et al. Development of disease activity and damage indices for myositis-initial testing of 4 tools in juvenile dermatomyositis Arthritis and Rheumatism 44 2001 S294
34. Bode R.K. Klein-Gitelman M.S. Miller M.L. et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence Arthritis and Rheumatism 49 2003 7-15
35. Guzman J. Petty R.E. Malleson P.N. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes Journal of Rheumatology 21 1994 739-743
36. Maillard SM, Jones R, Owens C, et al. Quantitative assessment MRI T2 relaxation time & thigh muscles in children with dermatomyositis. Rheumatology 2004; 43: 603-608.
37. Al-Mayouf S. Al-Mazyed A. Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate Clinical Rheumatology 19 2000 13-141
38. Fisler R.E. Liang M.G. Fuhlbrigge R.C. et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis Journal of American Academy of Dermatology 47 2002 505-511
39. Al-Mayouf S.M. Laxer R.M. Schneider R.et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety Journal of Rheumatology 27 2000 2498-503
40. Zeller V. Cohen P. Prieur A.M. et al. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases Journal of Rheumatology 23 1996 1424-1427
41. Kobayashi I. Yamada M. Takahashi Y. et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A Rheumatology 42 2003 371-374
42. Riley P. Maillard S. Wedderburn L.R. et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis - a review of efficacy and safety Journal of Rheumatology 2004 43: 491-496
43. Maillard S. Wilkinson N. Riley P. et al. The treatment of severe idiopathic myositis with anti-TNF therapy Arthritis and Rheumatism 44 supplement 2002 S307
44. Miller M.L. Smith R. Abbott K.A. et al. Use of etanercept in chronic juvenile dermatomyositis Arthritis and Rheumatism 44 supplement 2002 S306
45. Levine T.D. A pilot study of rituximab therapy for refractory dermatomyositis Arthritis and Rheumatism 46 2002 S488
46. Arora M, Maillard SM, Riley P et al. Marked improvement in a child with severe refractory juvenile dermatomyositis treated by autologous stem cell transplantation. Submitted for publication.
47. McDouall R.M. Dunn M.J. Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy Journal of Neurological Science 99 1990 199-217
48. Nagaraju K. Raben N. Loeffler I. et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies Proceedings of the National Academy of Sciences of the USA 97 2000 9209-9214
49. Pachman L.M. Litt D.L. Rowley A.H. et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis Arthritis and Rheumatism 38 1995 1513-1518
50. Tezak Z. Hoffman E.P. Lutz J.L. et al. Gene expression profiling in DQA1*0501+children with untreated dermatomyositis: a novel model of pathogenesis Journal of Immunology 168 2002 4154-4163
51. Massa M. Costouros N. Mazzoli F. et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis Arthritis and Rheumatism 46 2002 3015-3025
52. Englund P. Nennesmo I. Klareskog L. et al. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue Arthritis and Rheumatism 46 2002 1044-1055
53. Fedczyna T.O. Lutz J. Pachman L.M. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele Clinical Immunology 100 2001 236-239
54. Bartoli C. Civatte M. Pellissier J.F. et al. CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies Acta Neuropathologica 102 2001 385-392
55. Englund P. Lindroos E. Nennesmo I. et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies American Journal of Pathology 159 2001 1263-1273
56. Behrens L. Kerschensteiner M. Misgeld T. et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions Journal of Immunology 161 1998 5943-5951
57. Crowe W.E. Bove K.E. Levinson J.E. et al. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis Arthritis and Rheumatism 25 1982 126-139
58. Kissel J.T. Mendell J.R. Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis New England Journal of Medicine 314 1986 329-334
59. O'Gorman M.R. Corrochano V. Roleck J. et al. Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis Clinical and Diagnostic Laboratory Immunology 2 1995 205-208
60. Benveniste O. Cherin P. Maisonobe T. et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients Journal of Immunology 167 2001 3521-3529
61. Artlett C.M. Miller F.W. Rider L.G. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies Rheumatology 40 2001 1279-1284
62. Friedman J.M. Pachman L.M. Maryjowski M.L. et al Immunogenetic studies of juvenile dermatomyositis. HLA antigens in patients and their families Tissue Antigens 21 1983 45-49
63. Reed A.M. Pachman L. Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501 Human Immunology 32 1991 235-240
64. Reed A.M. Collins E.J. Shock L.P. et al Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule Journal of Immunology 159 1997 6260-6265
65. Shamim E.A. Rider L.G. Pandey J.P. et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis Arthritis and Rheumatism 46 2002 1885-1893
66. Pachman L.M. Liotta-Davis M.R. Hong D.K. et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications Arthritis and Rheumatism 43 2000 2368-2377
67. Rider L.G. Artlett C.M. Foster C.B. et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies Clinical and Experimental Immunology 121 2000 47-52
68. Maillard SM, Jones R, Owens C, et al. Benefits of exercise in the management of juvenile dermatomyositis - a new approach to physiotherapy. Arthritis and Rheumatism 2003; 48(9, suppl): S433